Intra-arterial infusion of 5-fluorouracil plus granulocyte-macrophage colony-stimulating factor (GM-CSF) and chemoembolization with melphalan in the treatment of disseminated colorectal liver metastases

European Journal of Surgical Oncology

Volumn 27, Issue 7, 2001, Pages 652-661

  Muller H ^a,b   Nakchbandi, W ^a,b   Chatzissavvidis, I ^a,b   Valek, V ^a,b  

^a Carl von Hess Hospital   (Germany)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Chemoembolization; Granulocyte macrophage colony stimulating factor (GM CSF); Liver metastases; Regional chemotherapy

Indexed keywords

BENDAMUSTINE; DEXAMETHASONE; DOXORUBICIN; FIBRINOLYTIC AGENT; FLUOROURACIL; FOLINIC ACID; GELFOAM; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IODINATED POPPYSEED OIL; LEVAMISOLE; MELPHALAN; MITOMYCIN; OXALIPLATIN; RALTITREXED;

ABDOMINAL PAIN; ADULT; ANGIOGRAPHY; ARTERY CATHETER; ARTERY THROMBOSIS; ARTICLE; ARTIFICIAL EMBOLISM; CANCER SURVIVAL; CHOLECYSTECTOMY; CHOLECYSTITIS; CIRCADIAN RHYTHM; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISSEMINATED CANCER; DOSE RESPONSE; DRUG RESPONSE; FEMALE; FEVER; GASTRODUODENAL ULCER; HEPATIC ARTERY; HUMAN; LEUKOPENIA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; VOMITING; WORLD HEALTH ORGANIZATION;

EID: 0035163818     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejso.2001.1193     Document Type: Article

References (64)

1. Trends in mortality from cancer in the European Union, 1955-1994
2. Survival in patients with large bowel cancer: A population based investigation from Melbourne colorectal cancer study
3. Epidemiologie des metastases hepatiques des cancer de colon
4. Cancer of the colon
5. Surgical resection of colorectal carcinoma metastases of the liver
6. Surgical margin in hepatic resection for colorectal metastases. A critical and improvable determinant of outcome
7. Liver resection on colorectal metastases
8. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer: Fondation Française de Cancerologie Digestive
9. Factors influencing the natural history of colorectal liver metastases
10. Survival impact of chemotherapy in patients with colorectal metastases confined to the liver: A re-analysis of 1458 non-operable patients randomised in 22 trials and 4 meta-analyses
11. Modulation of 5-fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate
12. Meta-Analyses of randomised trials testing biochemical modulation of 5-fluorouracil by Methotrexat in metastatic colorectal cancer
13. Efficacy of intravenous continuous infusion of 5-fluorouracil compared with bolus administration in advanced colorectal cancer
14. Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: Phase III trials
15. Irinotecan versus infusional 5-fluorouracil: A phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil
16. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6)
17. Intraarterial 5-fluorouracil and intravenous folinic acid in the treatment of liver metastases from colorectal cancer
18. Hepatic arterial infusion of chemotherapy alter resection of hepatic metastases from colorectal cancer
19. Perfusion of colorectal metastases: Relative flow distribution from the hepatic artery and portal vein
20. Intraarterial Therapy
21. The blood supply of experimental liver metastases. IV. Changes in vascularity with increasing tumour growth
22. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma-A randomized trial
23. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: The Northern California Oncology Group Trial
24. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases
25. Intra-arterial floxuridine vs. systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial
26. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: Long-term results of a prospective randomized trial
27. Quality of life and survival with continuous hepatic artery floxuridine infusion for colorectal liver metastases
28. Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells
29. Enhanced killing capacity of human Kupffer cells after activation with hGM-CSF and interferon gamma
30. Production and response of human prostate cancer cell lines to granulocyte macrophage-colony stimulating factor
31. Effect of granulocyte-macrophage colony stimulating factor on growth of a xenotransplanted human ovarian cancer cell line IGROV-1 in nude mice
32. Secretion of bioactive granulocyte-macrophage colony stimulating factor by human colorectal carcinoma cells
33. Effects of granulocyte-macrophage colony stimulating factor and interleukin-3 on small cell lung cancer cells
34. Establishment of large cell lung cancer lines secreting hematopoietic factors inducing leukocytosis and thrombocytosis
35. Granulocyte-macrophage colony-stimulating factor improves immunological parameters in patients with refractory solid tumours receiving second-line chemotherapy: Correlation with clinical responses
36. Cancer chronotherapy
37. Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: Feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion
38. Utility of embolization of chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma
39. Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of literature
40. The Edmonton Staging System
41. Measuring the cost-effectiveness of cancer care
42. A chemotherapeutic approach to colorectal carcinoma
43. Treatment options for patients with metastatic colorectal cancer
44. Arterial chemoembolisation with misroencapsulated anticancer drug. An approach to selective cancer chemotherapy with sustained effects
45. Hepatic artery infusion and chemoembolisation in the management of the liver
46. Pharmacologic rational for regional drug delivery
47. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte-macrophage colony stimulating factor plus interleukin-4 and downregulated by tumor necrosis factor alpha
48. Inhibition of tumor production of granulocyte-macrophage colony stimulating factor by 1 alpha, 25-dihydroxyvitamin D3 reduces tumor motility and metastasis
49. In vitro response of blasts to IL-3, GM-CSF and G-CSF is different for individual AML patients: Factors that stimulates leukemic clonogenic cells also enhances Ara-C cytotoxicity
50. Kinetics of human hemopoietic cells after in vivo administration of granulocyte-macrophage colony stimulating factor
51. Abrogating chemotherapy induced myelosuppression by recombinant granulocyte-macrophage colony stimulating factor: Protection at the progenitor level
52. Protracted continuous infusion of 5-fluorouracil and low-dose leucovorin in patients with metastatic colorectal cancer resistant to 5-fluorouracil bolus-based chemotherapy: A phase II study
53. Fundamentals: What is GM-CSF?
54. Continuous infusion or subcutaneous injection of granulocyte-macrophage-stimulating factor: Increased efficacy and reduced toxicity when given subcutaneously
55. Measurement of response to treatment in colorectal liver metastases
56. Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases
57. Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer
58. Cytarabine and cisplatin as salvage therapy in patients with metastatic colorectal cancer who failed 5-fluorouracil + folinic acid regimen
59. Immunotherapy with low-dose subcutaneous interleukin-2 plus beta-interferon as a second-line therapy for metastatic colorectal carcinoma
60. Second-line chemotherapy of advanced colorectal cancer with sequential high-dose methotrexate and 5-fluorouracil
61. Biomodulation with sequential intravenous IFN-alpha2b and 5-fluorouracil as second-line treatment in patients with advanced colorectal cancer
62. 5-Fluorouracil, high-dose folinic acid and mitonycin C combination chemotherapy in previously treated patients with advanced colorectal carcinoma
63. Sequential methotrexate and 5-fluorouracil as second-line chemotherapy for advanced colorectal cancer patients pretreated with 5-fluorouracil and leucovorin: A GISCAD study
64. Oral etoposide as second-line chemotherapy for colorectal cancer: A GISCAD study